Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
0.519
+0.029 (5.90%)
At close: Nov 4, 2024, 4:00 PM
0.510
-0.010 (-1.83%)
After-hours: Nov 4, 2024, 5:50 PM EST
Sensei Biotherapeutics Employees
Sensei Biotherapeutics had 28 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,059,714
Market Cap
13.05M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 28 | 0 | - |
Dec 31, 2022 | 28 | -28 | -50.00% |
Dec 31, 2021 | 56 | 24 | 75.00% |
Dec 31, 2020 | 32 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Cutera | 430 |
Evogene | 142 |
Cosmos Health | 123 |
Vivos Therapeutics | 123 |
ImmunoPrecise Antibodies | 101 |
STRATA Skin Sciences | 99 |
Biora Therapeutics | 58 |
CERo Therapeutics Holdings | 9 |
SNSE News
- 6 days ago - Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences - GlobeNewsWire
- 2 months ago - Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference - GlobeNewsWire
- 2 months ago - Sensei Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - GlobeNewsWire
- 6 months ago - EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member - Business Wire
- 6 months ago - Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire